CytoDyn Inc (QB) (CYDY) News

To be clear, you never mentioned buying when it was .11, but you are adding at .22? And this despite the fact you're here all the time and touting. Did you not like it at 11 cents? Did you have no faith in the company?

they often do this to fill large orders for certain clients.

I noticed the stink comes out just before a stock takes off. I grabbed some more on the dip today. A big shout out to the pigeons.

$$$$$$$CYDY$$$$$$$ 2025 and beyond.

Should they sell and why

Any thoughts on what investors should do since the weekend is here.
- Contemplating their CYDY losses
- Sharing these with their s’significant other
- Assessing if they have been manipulated in a pump & dump fraud
- Taking an appointment with a lawyer

“The fraud is dying, little by little.“

We will get there these things take time just keep posting.

Any thoughts on what investors should do since the weekend is here.

I’d still like to place a bet with you.

TIMBER

Every day a Cytodyn tree falls down.

The fraud is dying, little by little.

The price is going to revert to its low, little by little (2-5% per day) as it does every time.

Enjoy the company’s PR nothingburger, because that’s all you got. Now the excitement is leaving the ballroom of the Titanic, as every time.

WRITING IS ON THE WALL

Dec letter: "enrollment efforts are set to begin in January."

March letter: "we expect to start screening patients shortly."

How do longs not see what is going on here? How many times will CYDY play these games and longs not even see it? Does being so deep in the red really make people this stupid?

So you think are current CRO is fake, and what do you call the current CRC trial. Real or fake.

You are living in the past. Do you ever talk about anything new with the company or are you like Gro just stuck in the past.

Nothing about your post history screams long term share holder or supporter of the drug.

For sure. Been in since the nodder tried to do the reverse split and even got it on the ballot for shareholder vote. 2017-18??
Then later he pretended do be such a advocate for shareholders "we never do reverse split"--remember that nonsense??

Prob not--that is just history and FACT that does not fit your narrative/agenda

Prob (conveniently ) forgot about the nodder bragging about returning the govt funding with Drexel and that trial?? Doesn't fit your nonsense because its FACT

Sad the agenda of the flipper traders and their narrative. Real investors want real trials run--auth by FDA. With a real CRO (not kickback fraud). With real data assembly-diagnosed-submitted in correct format in timely manner.
Real investors want funding ATM--not your toxic below mkt free warrants nonsense to pad the "qualified". Real investors want the SEC and DOJ investigations over

Go away fairytale pharaoh. There has been enough sand thrown in the eyes . jimmy chuckles and misssusie got nothing on your brand of nonsense

Do you even own any shares?

Here is an old redthread where lonsford was discussed. And using company funds to pay someone that does not allow all interested to view the CYDY Facebook page. Even though all shareholders pay to fund his shenanigans. And posts fraud statements directly from nodder.

“For the avoidance of doubt, Chris Lonsford, Chief Operating Officer of Restorative Health, is not one of the Participants. While, he, as an individual, has been retained as a consultant by the Company, the Company has not authorized him or Restorative Health to solicit proxies on behalf of the Company.

https://www.sec.gov/Archives/edgar/data/1175680/000119312521282502/d246474dprec14a.htm


If you recall, Chris Lonsford is the head moderator for the CYDY Facebook investor page. He’d never disclosed that he was paid by CYDY until an investor discovered that his company, Restorative Health (who he is the COO of), is listed as a consultant for CYDY on their 2021 OTCQB certification. My understanding is that he is deleting posts on the FB page that question him being paid by CYDY or any post related to the topic.

Restorative Health - Chris L. is listed as the COO of Restorative Health on LinkedIn, Zoominfo and a few other sites.

https://www.linkedin.com/in/chris-lonsford-29a4a81b7

https://www.zoominfo.com/p/Chris-Lonsford/-950760961

Chris L’s Q&As with NP have been posted across many different investor message boards. Yes, CYDY planted a paid promoter as the moderator for the Facebook group with nearly as many members as the Reddit group.

https://www.facebook.com/groups/622470341583807/?ref=share

What investment advice would you give a new investor here.

TIMBER

Every day a Cytodyn tree falls down.

The price is going to revert to its low, little by little (2-5% per day) as it does every time.

Enjoy the company’s PR nothingburger, because that’s all you got. Now the excitement is leaving the ballroom of the Titanic, as every time.

WRITING IS ON THE WALL

Theswordman gave specific examples of the shady practices of the Cytodyn gang

As usual you reply with vague hand waving.

Not the first time - you did this with all my detailed posts too - I have provided detailed facts, complete with links to public legal documents, proving that Cytodyn has toxic debt, or that there was no « JAIDS trial » but only very old clinical data. And you could not provide a single fact to challenge it, only vague claims.

It’s very clear who has the facts and who is gaslighting

This statement is factually inaccurate on so many fundamental levels.

Advertising and making false statements and false claims are VERY different.

IF you do not grasp that by now--check into holds placed by FDA. Check into investigations by SEC and DOJ. Check into lawsuits from shareholders. Check into warning letter issued by FDA

Of course you can try like others and spin tales about shorts and 13D and big pharm--and all the other dodge defer deflect nonsense.
But nonsense is nonsense. Just like yours. Just like zerohedge. Just like phony audio tapes and Pestell fired for cause.

Just run trials. Stop with the conjecture and made up fairy tales. Adopt a mouse and move on. Sponsor a monkey and move along

Here is some wasted shareholder funds you find so necessary. Sure you know the alias
https://www.insiderfinancial.com/post/cytodyn-fda-letter-is-old-news-international-still-progressing

Leronlimab deserves better. Real shareholders don't need to waste funds on your nonsense or anyone elses

Also many probably don’t know but MMs are allowed to naked short OTC legally. Think about that.

Tell me more please.

Paying for advertising with shares is completely legal and more common than some realize, especially for startups or biotech firms.

Under the Securities Act of 1933, Section 4(a) (2) (15 U.S.C. § 77d(a) (2)) or Regulation D (like Rule 506(b)), companies can issue shares privately without SEC registration—no issue there. The SEC doesn't care unless there's fraud, misrepresentation, or an unregistered public offering. Take Chris, if he's hyping a drug he believes in and getting shares for it, that's just smart promoting something promising while earning equity. His confidence in the drug isn't an SEC problem, it's only if he's lying or scheming that they'd look twice.

Here is where you should be paying close attention, short sellers tanking the stock might actually draw more scrutiny those investigations can drag on for years and end in sealed indictments. If anyone thinks this share for ad setup is shady, they're missing how securities laws work. Do your homework or call the SEC if you're unsure.

Actually the key piece is the SEC filed doc that CYDY had to admit lonsford was paid by shareholder equity. What a waste of funds

Sad that ANYONE would support that facebook fraud. Hopefully the DOJ and SEC are still investigating these sheikhs, lonsfords, misssusies, gamblers, rabbits, dolphins, wolfs, jimmychuckjles etc. All innocent until convicted for their lies, fraud, deception, alias nonsense. All will be welcome in the khazempourhassan cell

And they blame FDA for the waste of years and millions of dollars

Leronlimab deserves better

You omitted a key piece of information:
This pump is coming from Chris Lonsford, a shady character according to this :

https://courts.delaware.gov/Opinions/Download.aspx?id=325470

The fish rots from the head (Nader Pourhassan the crook, the pump to $10 followed by a -99% fall to $0.10, etc…)

This smells so bad. The long thesis is incredibly fragile and stinky.

·From the FB page:
In my humble opinion something big is coming In cancer.
1. They put together an oncology board out of the blue.
2. The letter started with cancer & ended with “This is no longer a platform drug in search of an indication; we now have compelling data to support a role for leronlimab in solid-tumor oncology & are executing on that vision”.
3 “ leronlimab could play a significant role as a paradigm-shifting therapeutic in oncology”
4 “This is only the beginning of the Company’s 2025 oncology story”
5 “the developments in oncology have set the stage for 2025 to be a benchmark year for CytoDyn”
6 They are excited to share the results but can’t until after the ESMO conference.
7 They set up a new protocol to continue monitoring the survival patients
8 They began 2 preclinical’s in cancer & more importantly added a 3rd to “ further examine the apparent mechanism behind the observed increase in survival as compared to existing treatment paths”
9. Max’s post was all about mTNBC & not his HIV specialty
Buckle up!!

Uh oh gravity is resuming

The management’s « March update » is out…which ironically means…LOL…there is not much goodies left for March

Like every time.

Every time the stock is halved, and goes 5-10% below its previous low.

A smart long could sell, wait for this traditional consolidation, and buy back, doubling his/her shares for the same capital. Rince and repeat. There will be other spikes, easy money to be made.

I’ve laid out the facts, complete with clickable links and step-by-step instructions so you can verify them yourself.

And yet, your entire response boils down to « No, you’re wrong » without a shred of evidence.

If the CYDY long thesis is so rock-solid, surely you can find a clear evidence that there is new patient data, that doesn’t rely on wishful thinking?

Your memory is fading, you stated CYDY was indicted, remember, ask you to show this board where you saw that and of course crickets, because they weren’t indicted, oh, and im not angry, I don’t talk about the PPS, again you got it wrong, I didn’t ask you anything about our stock

I believe it was you who asked me what this stock was going to do regarding share price. My post was mysteriously deleted immediately.
Your answer is, what it is currently doing. It bounced to resistance, pump and dumpers dumped and now its headed back down once more. (I think I even listed the share price)
You guys get cocky when the stock goes up, and angry and looking to blame when it falls.
All the while it is doing what penny stocks do.
You are very angry, but at the wrong people.

I don't pretend to be anything. Your last post to me was rather ironic considering your sentence structure.

pretending to be a financial advisor when you aren’t I’d not very smart

It’s new they spent money on it. You can’t
facts.

You just don’t get.

It’s not old data. It shows how little you are involved with the scientific community just based on how you set yourself up for an argument you can’t win. You are so fixated on it being from CD02. It’s funny. Don’t get upset with something you don’t understand.

Be willing to learn. It’s new data you dug too deep.

it’s new application of the data.
Now you change the wording! "Application" was not in your posts before
You have made my point: it's NOT new data. It's very old data.

Fresh analysis with a tighter p-value (0.0008 vs. 0.0032)
Yep it's just a statistical analysis of OLD data. Rehash.
You get it, at last.
This type of analysis takes a couple minutes. Not exactly "busy work", particularly 3 years after the publication of the data. That was my point.

not a new trial we get that.
And you also recognize it, at last. You were claiming initially this was a new secret JAIDS trial (LOL the gross lie...like each of your posts...).

It’s new data.
Hum....no. You need to ensure some self-consistency. Let me help you: see above

The timing suggests that...
This is all assumptions in your mind.
The FACT is that it's old data, rehashed, and they have published nothing more.
No new study, no new data, nothing new there.

Enjoy the emptiness.

Here since Gro wants to argue here are examples.

• Trogarzo (ibalizumab-uiyk): Approved in 2018 for multidrug-resistant HIV, it relied on a tiny 40-patient trial and overcame initial skepticism. Like Leronlimab, it targeted a niche group with few options, and the FDA accepted its limited but strong data mirroring CytoDyn’s recent 52-patient OPTIMIZE trial showing a 64% viral load drop. Don’t even get me started on the BLA issues they had.

• Fuzeon (enfuvirtide): Greenlit in 2003, it had a troubled development with complex issues and doubts about practicality. It won approval by addressing patients failing other therapies, much like Leronlimab’s focus on multidrug-resistant HIV, proving the FDA can flex for unmet needs.

• Selzentry (maraviroc): A CCR5 antagonist like Leronlimab, it was approved in 2007 after efficacy and safety concerns. It succeeded by zeroing in on CCR5-tropic HIV patients, offering a precedent for CytoDyn to target a specific group and leverage its CCR5-blocking data.

These cases highlight that small trials and rocky histories don’t doom a drug if it meets a clear need good news for CytoDyn with its latest results and HIV niche

You can argue all you want it’s new application of the data.


• Published in February 2025: Fresh analysis with a tighter p-value (0.0008 vs. 0.0032).
• $10M R&D in 2024: Likely reanalyzed or added context to the old CD02 data. Not all 10 went to CRC.
• FDA hold lifted February 2024: Possible follow-ups or new lab work on the same cohort.

Still the same 52 patients and core stats, but the 2025 presentation and potential tweaks make it an updated take, not a new trial we get that. We don’t know what they did beyond that. Did they follow up.

It’s new data. Stop acting like they just wrote a paper about CD02 data and said here you go when it’s a different focus. They scrubbed the data from the last cro. Why would they do that.

It’s structured to clarify previous uncertainties in CD02 rather than conducting a fully new trial.

The timing suggests that CytoDyn may have conducted additional lab analysis on existing samples or used real-world patient follow-ups to strengthen safety and efficacy claims. You have the slightest idea how this works.


The stronger, more conclusive efficacy with cleaner data, the OPTIMIZE trial could serve as a pivotal component in their approval strategy.

The trial's goal-optimizing treatment for multidrug-resistant HIV-1. Neon signs all over

What does this have to do with the fact that this is new data.
Reading skills...I have written explicitly, several times, that this is old data, from 2015-2019, already released publicly in 2022.
Old stuff...you can't read my posts? You can't click on the link I have provided to the officiel clinical trials database proving that it was last updated in 2022?
LOL

What does this have to do with the fact that this is new data. New data. What CRO scrubbed the data. Proof of concept is step one.

Step one of what you probably have no clue.

FDA wants feasibility.

The "statistician" won't admit his figures are based on a corrupted CRO.
It's all he has to hang his hat on.
Does anyone think he doesn't know the real story? Only paid pigeons would
still be posting gibberish knowing the efficacy and safety of leronlimab.
So the question remains. Who is the paymaster? Would such a confession
ever be made outside a court of law? NO. There is no ignorance here at all.
Posting continually to manipulate the pps is the reason for payments. Sounds
like some Pigs and Pigeons are still a bit nervous as leronlimab knocks down
the lying narrative time and again.

Yahsho, undeniably, that draft when released is going to bring waves of attention.
There will be a number of PR's this year that will catch many off guard. What a year in store!!

Be factual. Stop pretending and talking without walking. I gave you the study ID, even the link to the official clinical trials website. I gave all the facts.
These are patients from 2015-2019, a very old treatment (more than 6 years ago), whose data has been collected a long time ago. And published a long time ago (2022).
Walk the talk.

So you just make stuff up now got it.

The safety of Leronlimab was already supposed to be proven in the BLA submission in 2020. That's the law. And that was 5 years ago. Hardly "busy work". 5 years and all that cash burnt!

“As previously announced, CytoDyn is preparing a manuscript summarizing the integrated safety data from the almost 1,600 patients who have already received leronlimab. The final draft of that safety summary will be completed shortly.“

Yea keep proving my point.

Actually it’s pretty common for it to work like this with a RTF. You must be new at this.
Again, safety information is a mandatory section of every BLA request. That's the process. You know this and are trying to spin it differently. Cytodyn has submitted the BLA in May 2020. Old stuff. Saying that an upcoming paper about this safety data is "busy work", 5 years after when it was submitted, is thus a lie.

A 5 years delay! Sluggish as hell

They were never good at data house keeping for the FDA.
Wrong. The clinical trials website shows all the data had been collected. You are again putting lipstick on the pig: this is an old 2015-2019 trial whose data was already released publicly in 2022. The patients were counted already a long time ago. There were roughly 50 of them, again in 2015 - 2019. OId, very old, stuff.

Not surprised that you try to pump that as new stuff. If you decide to invest based on that, you should trade in 2022 then! Easy prey for financial markets.

And he's messing with you also. That's the MO. Always. Surely you know this.

Can’t you see I’m messing with you. You need an NTC for a new trail. It’s new data stop arguing over facts. Yes they had to use CD02 patients.

You don’t get it. The hold never stopped retroactive study. You don’t think the doctors did blood draws on them. Man you don’t get it. JAIDS emphasizes 24-week outcomes and per-protocol p-values (0.0008 vs. CDO2's 0.0032)-looks like refined data to me.

Full stop. I saw them pull AEs on the 11th bc of Larvol updated.

Either they pulled them to appease a partner or they are preparing something for HIV. They were never good at data house keeping for the FDA.

It’s interesting you disagree with everything I say.

Wrong. Old patients new data.

Actually it’s pretty common for it to work like this with a RTF. You must be new at this.

Hey Gro, I get why you might think the leronlimab OPTIMIZE trial data isn’t new, but hear me out it absolutely is. This study just wrapped up its 25-week run in 2024, testing leronlimab on multidrug-resistant HIV-1 patients across 21 U.S. hospitals, and the results dropped in JAIDS last month, February 2025. That’s about as fresh as it gets! They showed 64% of patients hitting a solid viral load drop in just one week, stats that reflect today’s resistance patterns, not some old playbook.

If you couldn’t pick up on that here is why OPTIMIZE’s data differs from CD02. OPTIMIZE, run in 2024 and published February 2025, tests leronlimab (350 mg weekly) over 25 weeks in multidrug-resistant HIV-1 patients, showing 64% with a viral load drop in one week, but it digs deeper with 24 weeks of open-label data on optimized therapy. CD02, presented in 2019, was a shorter, single-dose study with a similar one-week stat (64%), but it didn’t track long-term outcomes like OPTIMIZE does. Different scope, fresh patients, updated resistance patterns that’s the difference.

Data’s fresh (2024-gathered)
Wrong. The FACTS:
the JAIDS paper rehashes the old 2015-2019 trial’s data, already released publicly in 2022. as I have already proven here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175940739

You specialize in disinformation - all your recent posts are contradicted by FACTS.

Sunshine is the best disinfectant.

Just busywork. Just busywork.
Wrong. The FACTS:

Safety data was supposed to be completed by Cytodyn in the fake BLA they had submitted in May 2020. It’s part of any FDA BLA…

5 years late is not « busywork ».

Sunshine is the best disinfectant.

The Antiviral Ace CytoDyn’s Been Hiding in Plain Sight?Picture this⚠️

Multidrug-resistant HIV-1, a beast that laughs at failing ART regimens, meets its match. The OPTIMIZE trial (JAIDS, Feb 20, 2025) drops a bombshel , leronlimab CCR5-blocking monoclonal antibody, isn’t just playing inflammation traffic gaurd ; it’s a full-on antiviral assassin. One week in, 64% of MDR HIV patients on leronlimab see a ≥0.5 log10 viral load drop (p=0.0032) vs. 23% on placebo. By 24 weeks with optimized background therapy, most are below 50 copies/mL undetectable. Gro this is amazing.

This isn’t a fluke to is where it’s a masterpiece⚡️

Why It Works Brilliantly?HIV sneaks into CD4+ T-cells via CCR5. Leronlimab slams the door shut, starving the virus before it can replicate. MDR patients’ ART fails because resistance mutations outsmart pills,leronlimab doesn’t care. It hits the host’s CCR5, not the virus’s mutating guts. In one week, it slashes RNA copies 3-fold, no resistance loopholes. Then, paired with OBT, it locks HIV down long-term. Antiviral, not just anti-inflammatory don’t let the cytokine-calm-down hype (COVID, cancer) fool you.

Here, it’s all about HIV RNA, not IL-6.
The Picture’s Clear?This isn’t a side gig. OPTIMIZE’s 52 patients (25 leronlimab, 27 placebo) across 21 U.S. centers, with p-values like 0.0008 (per-protocol), scream Phase 2b/3 precision. Add the 1,600-patient safety manuscript “shortly” due (March 17, 2025, letter), and it’s a BLA canvas efficacy inked, safety framed.

Cytodyn been burned by hype (2020 BLA flop, COVID overreach), but this? This is deliberate. Dr. Lalezari’s “benchmark year” isn’t just oncology it’s HIV-MDR salvation, weekly shots trumping daily pills like maraviroc. Tony knows it, I knew the day he got hired he saw his baby fate.


Why It Makes Sense?MDR HIV’s a desperate corner patients out of options, virus mutating faster than ART can catch up. Leronlimab sidesteps the chaos, hits a fixed target (CCR5), and delivers. Data’s fresh (2024-gathered), stats are tight, and the FDA’s past hold (lifted 2024) is yesterday’s news. They’re quiet because…. And I’ll stop because I’m talking to myself.

It’s a neon sign 🪧